These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17577009)

  • 1. GAIN for loss: adalimumab for infliximab-refractory Crohn disease.
    Mannon P
    Ann Intern Med; 2007 Jun; 146(12):888-90. PubMed ID: 17577009
    [No Abstract]   [Full Text] [Related]  

  • 2. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
    Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
    Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
    Da W; Zhu J; Wang L; Lu Y
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
    Kabaçam G; Törüner M
    Turk J Gastroenterol; 2010 Mar; 21(1):107-12. PubMed ID: 20552736
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
    Haennig A; Bonnet D; Thebault S; Alric L
    Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
    [No Abstract]   [Full Text] [Related]  

  • 7. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J; Kucharzik T
    Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
    [No Abstract]   [Full Text] [Related]  

  • 9. [Adalimumab in Crohn's disease - data from real life].
    López San Román A; Van Domselaar M; Garrido E
    Rev Esp Enferm Dig; 2008 Nov; 100(11):671-5. PubMed ID: 19159169
    [No Abstract]   [Full Text] [Related]  

  • 10. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.
    Cravo M; Silva R; Serrano M
    BioDrugs; 2010 Dec; 24 Suppl 1():25-7. PubMed ID: 21175232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crohn's disease in patients who fail infliximab therapy: what does the future hold?
    Abreu MT
    Rev Gastroenterol Disord; 2007; 7 Suppl 1():S20-6. PubMed ID: 17392630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease.
    Brandse JF; Peters CP; Gecse KB; Eshuis EJ; Jansen JM; Tuynman HA; Löwenberg M; Ponsioen CY; van den Brink GR; DʼHaens GR;
    Inflamm Bowel Dis; 2014 Feb; 20(2):251-8. PubMed ID: 24378599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The classics in perspective.
    Panés J; Ghosh S
    Gut; 2007 Sep; 56(9):1184-6. PubMed ID: 17698863
    [No Abstract]   [Full Text] [Related]  

  • 15. Commentary: infliximab or adalimumab in Crohn's disease?
    Sprakes MB; Hamlin PJ
    Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
    [No Abstract]   [Full Text] [Related]  

  • 16. Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy.
    Broge T; Nguyen N; Sacks A; Davis M
    Inflamm Bowel Dis; 2013 Apr; 19(5):E75-7. PubMed ID: 23435403
    [No Abstract]   [Full Text] [Related]  

  • 17. Summaries for patients. Treatment of Crohn disease with anti-tumor necrosis factor agent.
    Ann Intern Med; 2007 Jun; 146(12):I20. PubMed ID: 17470825
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
    Lopez-Sanroman A; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
    Tursi A; Elisei W; Picchio M; Penna A
    Aliment Pharmacol Ther; 2013 Apr; 37(7):763-4. PubMed ID: 23458543
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment with adalimumab in infliximab-resistant Crohn's disease.
    Barthel HR; Gille T; Halbsguth A; Kramer M
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1464-5. PubMed ID: 16105142
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.